IP Library Granted Patent US 9,522,120
Granted Patent B2
US 9,522,120 · App. 14/045,671 · Granted Dec 20, 2016

Compositions and methods of making sustained release liquid formulations

Inventors: Mark Tengler (Colleyville, TX); Paul Taskey (Richard Hills, TX); Daniel Lockhart (Euless, TX); Russell McMahen (Flower Mound, TX)
Assignee: NEOS THERAPEUTICS, LP
A61K9/5078A61K9/0095A61K9/10A61K9/1629A61K36/02A61K36/06A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,522,120
App. No.
14/045,671
Granted
Dec 20, 2016
Kind
B2
Abstract

The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles.

Claims (28)

1. A liquid, controlled-release formulation comprising controlled release microbeads comprising one or more active agents in coated drug-resin complexes and a dense, thixotropic solution having a density that is at or about the density of the one or more microbeads,

wherein said formulation is shelf-stable and has a uniform appearance with no visible lumps, and

further wherein said formulation is made by the method of

obtaining one or more controlled release microbeads comprising one or more active agents in coated drug-resin complexes;

preparing a dense, thixotropic solution having a density that is at or about the density of the one or more microbeads, under conditions that reduce bubble formation; and

mixing the microbeads and the solution under conditions that minimize the introduction of bubbles in the liquid.

2. The liquid formulation of claim 1 , wherein the one or more active agents comp rises pseudophedrine, an antihistamine, chlorpheniramine, dextromethorphan, an analgesic, an antitussive, or salts thereof or mixtures thereof.

3. A liquid, controlled-release formulation comprising controlled release beads comprising one or more active agents in coated drug-resin complexes and a dense, thixotropic solution having a density that is at or about the density of the one or more beads,

wherein said formulation is shelf-stable and has a uniform appearance with no visible lumps, and

further wherein said formulation is made by the method of

blending one or more controlled release beads comprising one or more active agents in coated drug-resin complexes with a dense, thixotropic solution having a density that is at or about the density of the one or more beads, under conditions that minimize air bubbles which cling to said beads.

4. The liquid formulation of claim 3 , wherein said method comprises the step of blending a mixture comprising one or more controlled-release beads comprising one or more active agents, a thickening agent and a surfactant by mixing with a low cavitation propeller and recirculating the mixture under the surface of the mixture so as to minimize bubble formation.

5. The liquid formulation of claim 1 , wherein the one or more microbeads comprise one or more of the following: an enteric coat, a resin coat, a lacquer coat, a pH-sensitive coating, a biodegradable polymer matrix, a water soluble matrix, an ionic matrix, combinations and mixtures thereof.

6. The liquid formulation of claim 1 , wherein the one or more microbeads comprise one or more polymers selected from the group consisting of cellulose, ethylcellulose, methylcellulose, propylcellulose, methoxypropylcellulose, cellulose nitrate, poly(vinyl alcohol), poly(vinyl chloride), polystyrene, polyethylene, polypropylene, poly(ethylene-co-vinyl acetate), poly(hydroxybutyric acid), poly(hydroxyvalerianic acid-co-hydroxybutyric acid), poly(lactic acid), poly(glycolic acid), poly(lactic acid-co-glycolic acid), poly(ε-caprolactones), poly(ε-caprolactone-co-DL-lactic acid), poly(maleic anhydride), polyamides, gelatin, chitosan, collagen, poly(hydroxyalkyl)-L-glutamines, poly(γ-ethyl-L-glutaminate-co-glutamic acid), poly(L-leucine-co-L-aspartic acid), poly(proline-co-glutamic acid), poly(alkyl 2-cyanoacrylates), polyurethanes, poly(methyl methacrylate), poly(methyl methacrylate-co-methacrylic acid) and poly(methacrylate-co-hydroxypropyl methacrylate), polystirex, salts, combinations and mixtures thereof.

7. The liquid formulation of claim 1 , wherein the conditions that minimize the introduction of bubbles comprise the step of sprinkling the beads onto the surface of the liquid, and/or the step of mixing the solution in the absence of paddles that scrape the vessel.

8. The liquid formulation of claim 1 , wherein the conditions that reduce bubble formation and/or minimize the introduction of bubbles comprise: the step of mixing the solution with a propeller mixer; the step of mixing the solution with a propeller mixer at a speed that reduces cavitation; the step of mixing the solution with a propeller that minimizes cavitation; the step of placing the recirculating tube below the surface of the liquid; and/or the step of adding liquids along the side of a vessel holding the liquid.

9. The liquid formulation of claim 1 , wherein the conditions that reduce bubble formation and/or minimize the introduction of bubbles comprise the steps of placing a recirculating tube below the surface of the liquid, adding liquids along the side of a vessel holding the liquid, and using a mixer that lacks scraping paddles.

10. The liquid formulation of claim 1 , wherein said formulation further comprises one or more active agent containing beads having an immediate release profile.

11. The liquid formulation of claim 1 , wherein the formulation further comprises one or more flavorants, one or more surfactants, one or more dissolved active agents, one or more buffers, one or more excipients, or mixtures and combinations thereof.

12. The liquid formulation of claim 1 , wherein the one or more active agents are pharmaceutical agents, vitamins, minerals, nutritional supplements, herbal extracts, oils, salts, or mixtures and combinations thereof.

13. The liquid formulation of claim 1 , wherein the one or more active agents is/are pharmaceutical agents selected from the group consisting of proteins, peptides, carbohydrates, polysaccharides, glycoproteins, lipids, hormones, growth factors, cytokines, interferons, receptors, antigens, allergens, antibodies, antiviral agents, antifungal agents, antihelminthic agents, metabolites, cofactors, inhibitors, drugs, pharmaceuticals, nutrients, toxins, poisons, pesticides, chemical warfare agents, prions, radioisotopes, vitamins, heterocyclic aromatic compounds, carcinogens, mutagens, narcotics, amphetamines, barbiturates, hallucinogens, and combinations and mixtures thereof.

14. The liquid formulation of claim 1 , wherein the one or more active agents comprise a pharmaceutical agent, an enzyme, a cytokine, a growth promoting agent, an antibody, an antigen, a hormone, a vaccine, a peptide, a carbohydrate, a nucleic acid, a lipid, or mixtures and combinations thereof.

15. The liquid formulation of claim 1 , wherein the one or more active agents is/are selected from the group consisting of: steroids, respiratory agents, sympathomimetics, local anesthetics, antimicrobial agents, antiviral agents, antifungal agents, antihelminthic agents, insecticides, antihypertensive agents, antihypertensive diuretics, cardiotonics, coronary vasodilators, vasoconstrictors, β-blockers, antiarrhythmic agents, calcium antagonists, anti-convulsants, agents for dizziness, tranquilizers, antipsychotics, muscle relaxants, drugs for Parkinson's disease, respiratory agents, hormones, non-steroidal hormones, antihormones, vitamins, antitumor agents, miotics, herb medicines, antimuscarinic, interferons, immunokines, cytokines, muscarinic cholinergic blocking agents, mydriatics, psychic energizers, humoral agents, antispasmodics, antidepressant drugs, anti-diabetics, anorectic drugs, anti-allergenics, decongestants, expectorants, antipyretics, antimigrane, anti-malarials, anti-ulcerative, peptides, anti-estrogen, anti-hormone agents, antiulcer agents, anesthetic agent, drugs having an action on the central nervous system, proteins, carbohydrates, polysaccharides, glycoproteins, lipids, hormones, growth factors, cytokines, receptors, antigens, allergens, antibodies, metabolites, cofactors, inhibitors, drugs, pharmaceuticals, nutrients, toxins, poisons, pesticides, chemical warfare agents, prions, radioisotopes, vitamins, heterocyclic aromatic compounds, carcinogens, mutagens, narcotics, amphetamines, barbiturates, hallucinogens, and vaccines against viruses, bacterium, fungi, helminths, cancers, Salmonella, Streptococcus, Brucella, Legionella, E. coli, Giardia, Cryptosporidium, Rickettsia , spores, molds, yeasts, algae, amoebae, dinoflagellates, unicellular organisms, and pathogens, and combinations and mixtures thereof.

16. The liquid formulation of claim 1 , wherein the one or more active agents are disposed on a poly-lactic acid (PLA), poly-glycolic acid (PGA) and/or poly-lactic polyglycolic acid (PGLA) bead.

17. A liquid, controlled-release formulation comprising controlled release microbeads comprising one or more active agents in coated drug-resin complexes, a dense, thixotropic solution having a density that is at or about the density of the one or more microbeads, said dense, thixotropic solution comprises a thixotropic agent, water and one or more preservatives,

wherein said formulation is shelf-stable and has a uniform appearance with no visible lumps.

18. The liquid, controlled-release of claim 17 , wherein the microbeads are free of bubbles that cling to said microbeads and change their nominal density.

19. The liquid formulation of claim 1 , wherein said solution comprises a thixotrophic agent, water, and one or more preservatives.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jun 14, 2024
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: NEOS THERAPEUTICS, LP
Reel/Frame 067728/0327 →
RELEASE OF SECURITY INTEREST Recorded Mar 12, 2024
From: DEERFIELD MGMT, L.P.
To: NEOS THERAPEUTICS, LP
Reel/Frame 066725/0043 →
SECURITY INTEREST Recorded Feb 10, 2022
From: NEOS THERAPEUTICS, LP
To: AVENUE VENTURE OPPORTUNITIES FUND II, L.P.
Reel/Frame 058977/0069 →
SECURITY INTEREST Recorded Oct 7, 2019
From: NEOS THERAPEUTICS, LP
To: DEERFIELD MGMT, L.P., AS COLLATERAL AGENT
Reel/Frame 050638/0952 →
SECURITY INTEREST Recorded Oct 2, 2019
From: NEOS THERAPEUTICS, LP
To: ENCINA BUSINESS CREDIT, LLC, AS AGENT
Reel/Frame 050606/0096 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2014
From: TENGLER, MARK; TASKEY, PAUL; LOCKHART, DANIEL; MCMAHEN, RUSSELL
To: NEOS THERAPEUTICS, LP
Reel/Frame 032977/0966 →
Continuity (3)
Continuation 13685496 · Nov 26, 2012
Continuation 11068124 · Feb 28, 2005
Related Publication 20140093577A1 · Apr 3, 2014